Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Ironwood Pharmaceuticals, Inc.    IRWD

SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
 News SummaryMost relevantAll newsSector newsTweets
Most relevant news about IRONWOOD PHARMACEUTICALS,
09/08 IRONWOOD PHARMACEUTICALS : Announces Leadership Change
09/08 VERTEX PHARMACEUTICALS : Appoints Tom Graney as Senior Vice President and Chief ..
09/06 IRONWOOD PHARMACEUTICALS : Announces Leadership Change
08/31 IRONWOOD PHARMACEUTICALS : to Present at Upcoming September Investor Conferences
08/22 IRONWOOD PHARMACEUTICALS : Announces FDA Approval of DUZALLO for the Treatment o..
08/22 BIOTECH MOVERS : Cardiome Pharma Corp. (NASDAQ:CRME), Coherus BioSciences, Inc. ..
08/21 IRONWOOD PHARMACEUTICALS : Announces FDA Approval of DUZALLO® (lesinurad and all..
08/04 IRONWOOD PHARMACEUTICALS : reports 2Q loss
08/03 IRONWOOD PHARMACEUTICALS,INC. (NASDA : IRWD) Files An 8-K Results of Operations ..
08/03 IRONWOOD PHARMACEUTICALS : Provides Second Quarter 2017 Investor Update
07/21 HERE’S WHAT JUST HAPPENED WITH : IRWD) and Aeterna Zentaris Inc. (NASDAQ:A..
07/20 IRONWOOD PHARMACEUTICALS : to Host Second Quarter 2017 Investor Update Call
07/20 IRONWOOD PHARMACEUTICALS : Reports Positive Top-line Results from IW-3718 Phase ..
06/08 IRONWOOD PHARMACEUTICALS : to Present at the Goldman Sachs 38th Annual Global He..
06/01 IRONWOOD PHARMACEUTICALS : to Present at the Jefferies Healthcare Conference
More most relevant news
All news about IRONWOOD PHARMACEUTICALS,
09/14 IRONWOOD PHARMACEUTICALS : Announces Leadership Change
09/08 IRONWOOD PHARMACEUTICALS : Announces Leadership Change
09/08 VERTEX PHARMACEUTICALS : Appoints Tom Graney as Senior Vice President and Chief ..
09/06 IRONWOOD PHARMACEUTICALS INC : Change in Directors or Principal Officers, Financ..
09/06 IRONWOOD PHARMACEUTICALS : Announces Leadership Change
08/31 IRONWOOD PHARMACEUTICALS : to Present at Upcoming September Investor Conferences
08/31 IRONWOOD PHARMACEUTICALS : Announces FDA Approval of DUZALLO® lesinurad and allo..
08/22 IRONWOOD PHARMACEUTICALS : Announces FDA Approval of DUZALLO for the Treatment o..
08/22 BIOTECH MOVERS : Cardiome Pharma Corp. (NASDAQ:CRME), Coherus BioSciences, Inc. ..
08/22 IRONWOOD PHARMACEUTICALS : looks to boost gout franchise as FDA delivers OK for ..
More news
Sector news : Biotechnology & Medical Research - NEC
09/20DJSANOFI : Alnylam Report Positive Patisiran Phase III Trial, First-Ever for RNAi ..
09/15 Drug industry on tenterhooks as Maryland price-gouging law nears
09/07 New AstraZeneca, Amgen drug looks strong rival in severe asthma
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag -- Update
08/30DJFDA Approves Pioneering Cancer Treatment With $475,000 Price Tag
08/29DJGILEAD SCIENCES : Bets $11 Billion On New Cancer Therapy -- WSJ
More sector news : Biotechnology & Medical Research - NEC
News from SeekingAlpha
09/21 Continued Trouble Ahead For Ardelyx
09/20 Allergan, And Linzess' Misleading Side Effects
09/06 Ironwood Pharma finance chief leaves for Vertex; shares down 2%
08/29 SYNERGY PHARMACEUTICALS : Risky But Still A Buy
08/23 3 THINGS IN BIOTECH YOU SHOULD LEARN : August 23, 2017
08/21 FDA OKs Ironwood's Duzallo for gout-related hyperuricemia
Latest Tweets
09/24Blue Jay Capital Management LLC Sells 205,000 Shares of Ironwood Pharmaceutic.. 
09/24$IRWD - Blue Jay Capital Management LLC Sells 205,000 Shares of Ironwood Phar.. 
09/18Ironwood Pharmaceuticals, Inc. $IRWD Position Increased by Oppenheimer Asset .. 
09/15American Century Companies Inc. Sells 12,103 Shares of Ironwood Pharmaceutica.. 
09/13Want the latest analyst ratings on $IRWD $SNPS $CZNC $MGRC $VLPNY? Get Them D.. 
More tweets
Qtime:16
Financials ($)
Sales 2017 273 M
EBIT 2017 -126 M
Net income 2017 -162 M
Debt 2017 282 M
Yield 2017 -
P/E ratio 2017 -
P/E ratio 2018
EV / Sales 2017 9,70x
EV / Sales 2018 6,82x
Capitalization 2 370 M
Chart IRONWOOD PHARMACEUTICALS,
Duration : Period :
Ironwood Pharmaceuticals,  Technical Analysis Chart | IRWD | US46333X1081 | 4-Traders
Technical analysis trends IRONWOOD PHARMACEUTICALS,
Short TermMid-TermLong Term
TrendsBullishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 12
Average target price 17,2 $
Spread / Average Target 8,8%
EPS Revisions
Managers
NameTitle
Peter M. Hecht Chief Executive Officer & Director
Terrance G. McGuire Chairman
Gina R. Consylman CFO, CAO, Controller & VP-Finance
Mark G. Currie Chief Scientific Officer & Senior Vice President
Brian M. Cali Senior VP-Preclinical, Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
IRONWOOD PHARMACEUTICALS, INC.1.50%2 370
INCYTE CORPORATION14.74%23 351
QUINTILES IMS HOLDINGS INC23.89%20 370
LONZA GROUP56.52%19 634
CELLTRION, INC.--.--%15 568
ALNYLAM PHARMACEUTICALS, INC.201.60%10 439